tirzepatide hearing loss Stay Informed About Urgent Care Services Weight-loss drug approved to treat

Mounjaro can cause acute kidney damage

This is the same classification level required for commercial pharmaceutical manufacturing, not just compounding

Approved by the FDA for type 2 diabetes and chronic weight management, tirzepatide slows gastric emptying and stimulates receptors in the brainstem that trigger nausea

In the SURMOUNT-1 trial, which focused on weight loss and obesity treatment, significant weight loss was observed with Mounjaro

For non-diabetic individuals struggling with obesity, these medications can support significant weight loss , with clinical trials showing an average reduction of 10-15% of body weight while also improving metabolic health and blood sugar regulation